Parkinson's disease
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria (healthy volunteers) Age over 40 Informed consent;Inclusion criteria (patients) -Age over 40 -Informed consent. -Regarded by the treating physician to have competence of judgement. -Compliance with the criteria for possible or probable PD as proposed by Gelb, Oliver and Gilman [1999] -de novo PD without PD medication, or advanced PD with Hoehn and Yahr stage of at least 2.
Exclusion criteria
Exclusion criteria: Exclusion criteria (all PET-study subjects) - Prior cardiovascular brain disease, other brain disease (including former traumatic contusion) - Evidence of any general medical disease, e.g. significant kidney or liver disease, evidence of autoimmune disease. - Use of anti-inflammatory medication: NSAID*s and steroids. - Use of benzodiazepines. Benzodiazepines have affinity for the PBR receptor that binds the PET tracer PK11195 and can interfere with the study. - Abnormalities at clinical neurological examination - Pregnancy in women of childbearing potential. - Exposure to a significant amount of radiation in the past year. - Radiological workers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uptake of the radiolabeled PK11195 measured with PET as a measure of activated microglia in neuroinflammation. The groups will be statistically compared using an SPM programme. | — |
Countries
Netherlands
Outcome results
None listed